Posted by Michael Wonder on 29 May 2025
Capsida receives FDA fast track designation for its potential first in class IV administered gene therapy for STXBP1 developmental and epileptic encephalopathy
29 May 2025 - Capsida previously received FDA orphan drug designation and IND clearance to initiate the SYNRGY Phase 1/2a clinical trial for CAP-002.
Capsida Biotherapeutics today announced the US FDA has granted fast track designation to its CAP-002 program.
